Validation of the Kidney Disease Quality of Life (KDQOL) Cognitive Function subscale  by Kurella, Manjula et al.
Kidney International, Vol. 66 (2004), pp. 2361–2367
Validation of the Kidney Disease Quality of Life (KDQOL)
Cognitive Function subscale
MANJULA KURELLA, JENNIFER LUAN, KRISTINE YAFFE, and GLENN M. CHERTOW
Divisions of Nephrology, and Psychiatry, Neurology, and Epidemiology, Department of Medicine, University of California San
Francisco; Moffitt-Long Hospitals, UCSF-Mt. Zion Medical Center; and San Francisco Veterans Affairs Medical Center, San
Francisco, California
Validation of the Kidney Disease Quality of Life (KDQOL)
Cognitive Function subscale.
Background. Formal cognitive function testing is cumber-
some, and no self-administered instruments for estimating cog-
nitive function in persons with chronic kidney disease (CKD)
and end-stage renal disease (ESRD) have been validated. The
goal of this study was to determine the validity of the Kidney
Disease Quality of Life Cognitive Function scale (KDQOL-
CF) for the assessment of cognitive impairment in persons with
kidney disease.
Methods. We administered the KDQOL-CF to 157 subjects,
79 with ESRD and 78 with CKD participating in a cross-
sectional study of cognitive function. Scores on the Modified
Mini-Mental State Exam (3MS) were considered the gold stan-
dard measure of global cognitive function. Performance char-
acteristics of the KDQOL-CF were assessed using correlation
coefficients, Bland-Altman plots, and receiver operating char-
acteristic curves.
Results. Median scores on the KDQOL-CF were 73 (in-
terquartile range 60–87) for subjects with ESRD and 87 (in-
terquartile range 73–100) for subjects with CKD (P < 0.0001).
Scores on the KDQOL-CF were directly correlated with scores
on the 3MS (r = 0.31, P = 0.0001). Defining global cogni-
tive impairment as a 3MS score <80, a cut-point of 60 on the
KDQOL-CF accurately classified 76% of subjects, with 52%
sensitivity and 81% specificity. On multivariable analysis, cere-
bral and peripheral vascular disease, benzodiazepine use, and
higher serum phosphorus concentrations were associated with
lower KDQOL-CF scores, while beta blocker use, education,
and higher serum albumin concentrations were associated with
higher KDQOL-CF scores.
Conclusion. The KDQOL-CF is a valid instrument for es-
timating cognitive function in patients with CKD and ESRD.
KDQOL-CF screening followed by 3MS testing in selected in-
dividuals may prove to be an effective and efficient strategy
for identifying cognitive impairment in patients with kidney
disease.
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Cognitive impairment is a common, often unrecog-
nized condition in persons with end-stage renal disease
(ESRD) [1]. Cognitive impairment is associated with
more frequent hospitalizations and greater utilization of
health care resources in patients with ESRD [1]; in the
general population dementia carries an increased risk of
death and higher health care costs [2]. Little is known
about cognitive impairment in persons with chronic kid-
ney disease (CKD) not yet requiring dialysis. Never-
theless, accurate identification of patients with cognitive
impairment is central to reducing the considerable mor-
bidity associated with this condition. Formal cognitive
function testing requires trained personnel and can be
time consuming, even when employing screening tests of
global cognitive function, such as the Mini-Mental Sta-
tus Examination (MMSE). A reliable self-administered
questionnaire for the identification of cognitive impair-
ment would be extremely valuable for physicians and
others caring for persons with CKD and ESRD.
The Kidney Disease Quality of Life (KDQOL) instru-
ment is a self-administered questionnaire designed to as-
sess health-related quality of life in persons with kidney
disease. The KDQOL contains eight subscales derived
from the Medical Outcomes Study SF-36 [3], as well as
12 kidney disease targeted subscales, including cognitive
function [4]. There are several potential advantages of
such an instrument to assess cognitive function, including
its brevity and ease of administration and interpretation.
Additionally, the KDQOL has been used to assess quality
of life in several ongoing and recently completed cohort
studies in CKD and ESRD [5–7], facilitating comparisons
among different patient groups. Despite widespread use
of the KDQOL, the cognitive function subscale has not
been validated against objective measures of cognitive
function.
Therefore, we sought to determine the sensitivity,
specificity, and positive and negative predictive values
of the KDQOL cognitive function scale (KDQOL-CF)
compared with an objective measure of global cognitive
function, the Modified Mini-Mental State Exam (3MS) in
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subjects with CKD and ESRD. Using performance char-
acteristics of the KDQOL-CF and the 3MS and a broad
range of prevalence estimates for cognitive impairment
in CKD and ESRD, we then determined the expected
diagnostic efficiency of a two-step screening strategy em-
ploying the KDQOL-CF and 3MS in sequence.
METHODS
We recruited subjects from three dialysis units and
ambulatory nephrology practices affiliated with the Uni-
versity of California San Francisco (UCSF) to partic-
ipate in a cross-sectional study of cognitive function.
These practices serve an ethnically and socioeconomi-
cally diverse population generally from within the city
of San Francisco. Subjects with ESRD received in-center
hemodialysis three times per week, using ultrafiltration
controlled machines, bicarbonate-based dialysate, and
high-flux polysulfone dialyzers for 3 to 4 hours per ses-
sion. Estimated GFR was calculated for subjects with
CKD using the six variable Modification of Diet in Re-
nal Disease (MDRD) study equation incorporating age,
black versus non-black race, sex, serum creatinine, urea
nitrogen, and albumin concentrations [8]. Subjects with
CKD were eligible to participate if they had an estimated
GFR <60 mL/min/1.73 m2 on at least two occasions dur-
ing the past 12 months. Subjects not fluent in English or
with significant hearing impairment were excluded. Par-
ticipation rates were >95% for screened subjects with
ESRD. Potential subjects with CKD were screened by
the treating nephrologist, and referred to the study if el-
igible; thus, participation rates were not determined for
subjects with CKD. The UCSF Committee on Human
Research approved the study, and all subjects signed in-
formed consent.
Cognitive function tests
Subjects underwent a battery of cognitive function tests
administered by two trained personnel. The 3MS is a
brief test of global cognitive function with components for
orientation, attention, language, and memory. The 3MS
has a maximum score of 100 (scores range from 0–100),
and is considered to be more sensitive for mild cogni-
tive impairment compared with the traditional 30-point
Mini-Mental Status Exam (MMSE) [9]. A 3MS <80 was
reported to have a sensitivity of 91% and specificity of
97% for detecting dementia in the general population
[9]. The 3MS was administered to subjects with ESRD
during a midweek hemodialysis session, avoiding the be-
ginning or end of each treatment. Subjects with CKD
underwent cognitive function testing during a clinic visit.
Subjects also completed the cognitive function subscale
of the Kidney Disease Quality of Life (KDQOL-CF)
short form and the Geriatric Depression Scale short form
(GDS). The cognitive subscale of the KDQOL consists
of three questions: During the past 4 weeks, did you react
slowly to things that were said or done? Did you have dif-
ficulty concentrating or thinking? Did you become con-
fused? Subject responses on a qualitative 6-point scale
were weighted and transformed to scores ranging from 0
to 100, with higher scores indicating better self-assessed
cognitive function [4]. The GDS is a 12-item scale measur-
ing symptoms of depression, with higher scores indicating
greater depressive symptoms [10]. The GDS has been val-
idated as a screen for depression among elderly subjects,
and specifically among those with cognitive impairments
[11]. Compared to the more widely used Beck Depres-
sion Inventory (BDI), the GDS is shorter and contains
fewer items (one of 12) querying somatic symptoms.
Statistical analysis
Continuous variables were expressed as mean ±
standard deviation or median with interquartile range.
Categorical variables were expressed as proportions.
Between-group differences were compared with Student
t test, the Wilcoxon rank-sum test, or the chi-square test,
where appropriate. Correlation was assessed with the
Pearson product moment coefficient. We used multivari-
able linear regression analysis to determine independent
predictors of the KDQOL-CF score. Companion analy-
ses stratified by the severity of kidney disease (i.e., ESRD
vs. CKD) were also performed. Based on the stratified
analyses, we considered several multiplicative interaction
terms to evaluate for effect modification by ESRD versus
CKD status. Variables that were not significantly associ-
ated with the KDQOL-CF score were added back to the
model individually to evaluate for residual confounding.
Residual plots showed normal distributions and no sig-
nificant outliers. We constructed a Bland-Altman plot to
determine agreement between the KDQOL-CF and 3MS
[12]. A receiver operator characteristic (ROC) curve was
constructed to determine the sensitivity and specificity
of the KDQOL-CF using different cut-points to define
self-reported cognitive impairment. Finally, we consid-
ered two hypothetical screening strategies for cognitive
impairment—one in which all potential participants were
screened with the 3MS, and another in which all poten-
tial participants were screened with the KDQOL-CF and
those with low KDQOL-CF scores were subsequently
screened with the 3MS. We calculated positive and nega-
tive predictive values and hypothetical costs over a wide
range of prevalence estimates. For all analyses, two-tailed
P values < 0.05 were considered significant. All analyses
were performed with STATA 8.0 (College Station, TX,
USA).
RESULTS
A total of 160 subjects were enrolled in the study;
157 completed the 3MS and KDQOL-CF. Subject
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Table 1. Characteristics of study subjects with chronic kidney disease
(CKD) and end-stage renal disease (ESRD)
CKD ESRD
Characteristic (N = 78) (N = 79) P value
Age years 63.8 ± 14.2 61.2 ± 14.4 0.25
Female % 23% 41% 0.02
Race %
Caucasian 54% 17% <0.0001
Black 26% 52%
Asian 17% 25%
Other 4% 6%
High school graduate % 93% 81% 0.04
Diabetes % 40% 54% 0.08
CHF% 21% 49% <0.0001
PVD % 18% 22% 0.57
Stroke % 27% 20% 0.32
Beta-blocker % 60% 63% 0.70
Benzodiazepine % 9% 9% 0.98
Opiate % 12% 20% 0.17
Antidepressant % 18% 11% 0.25
Weight kg 79.1 ± 16.7 73.5 ± 29.3 0.16
SBP mm Hg 137 ± 22 153 ± 26 <0.0001
DBP mm Hg 74 ± 13 82 ± 16 0.001
Vintage months — 40.9 ± 36.2 —
eGFR mL/min/1.73m2 26.6 ± 11.5 — —
Creatinine mg/dL 3.1 ± 2.0 9.4 ± 3.5 <0.0001
BUN mg/dL 51.2 ± 22.5 62.2 ± 21.2 0.002
Hemoglobin mg/dL 12.1 ± 1.5 11.9 ± 1.2 0.38
Calcium mg/dL 9.1 ± 0.8 9.2 ± 0.8 0.28
Phosphorus mg/dL 4.4 ± 1.1 5.6 ± 1.9 <0.0001
PTH ng/L 186 ± 139 388 ± 268 <0.0001
Geriatric Depression Scale 3 ± 3 5 ± 3 0.0008
Abbreviations are: CHF, congestive heart failure; PVD, peripheral vascular
disease; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone.
characteristics are shown in Table 1 stratified by CKD
status (CKD vs. ESRD). The mean age of all subjects was
62.5 ± 14.3 years. For subjects with CKD, the mean esti-
mated GFR was 26.6 ± 11.5 mL/min/1.73 m2. Subjects
with ESRD were more likely to be female, nonwhite,
and less likely to have graduated high school. Subjects
with ESRD also had a higher prevalence of congestive
heart failure, and a trend toward more diabetes mellitus.
As expected, there were significant differences in blood
pressure and serum concentrations of creatinine, urea ni-
trogen, phosphorus, and parathyroid hormone between
the ESRD and CKD groups.
Scores on KDQOL-CF and 3MS
Median scores on the KDQOL-CF were 73 (range 0–
100) for ESRD subjects, and 87 (range 20–100) in CKD
subjects (P < 0.0001). Eleven percent of subjects with
ESRD and 26% of subjects with CKD had scores at
the test ceiling on the KDQOL-CF. Only one subject
with ESRD, and no subjects with CKD, had KDQOL-CF
scores at the test floor. Median scores on the 3MS were
86 (range 45–99) for subjects with ESRD, and 94 (range
60–100) for subjects with CKD (P < 0.0001). Six percent
of subjects with CKD, and no subjects with ESRD, had
scores at the test ceiling on the 3MS; no subjects had
scores at the test floor.
There was a modest direct correlation between the
summary KDQOL-CF score and 3MS score (r = 0.31,
P = 0.0001). Item 3 querying symptoms of confusion was
most strongly correlated with 3MS score (r = 0.34, P <
0.0001). The KDQOL-CF was more strongly correlated
with the GDS (r = −0.56, P < 0.0001) than with the 3MS.
Among subjects with CKD, KDQOL-CF scores were in-
versely correlated with benzodiazepine use, serum phos-
phorus, and calcium × phosphorus product, and directly
correlated with years of education and serum albumin
(Table 2). Among subjects with ESRD, KDQOL-CF
scores were inversely correlated with the GDS, benzo-
diazepine use, and stroke, and directly correlated with
beta-blocker use.
Predictors of the KDQOL-CF score
Table 3 shows the final multivariable model predicting
the KDQOL-CF score. ESRD status, stroke, peripheral
vascular disease, benzodiazepine use, higher serum phos-
phorus, and lower serum albumin concentrations were
associated with lower KDQOL-CF scores. Beta-blocker
use and additional education were associated with higher
KDQOL-CF scores. The associations of education and
albumin with KDQOL-CF scores were dependent on
ESRD status. No other ESRD × covariate interaction
terms were statistically significant, suggesting a relatively
uniform association by stage of kidney disease. The model
explained 42% of the variance in KDQOL-CF score.
Since depression and cognitive function are closely
linked, we fit companion models including the GDS
score. With addition of the GDS, 52% of the variation in
KDQOL-CF was explained. The parameter coefficients
and P values were essentially unchanged, except that the
fixed effect of serum albumin (P = 0.07) and the ESRD
× education interaction term (P = 0.06) were no longer
statistically significant by the P < 0.05 criterion.
Bland-Altman plot and ROC curve
A Bland-Altman plot suggested systematic differences
between KDQOL-CF scores and 3MS scores (Fig. 1).
Those with low 3MS scores tended to overestimate cogni-
tive function on the KDQOL-CF, whereas those with high
3MS scores tended to underestimate cognitive function
on the KDQOL-CF. Considering a 3MS <80 as indicative
of cognitive impairment, a KDQOL-CF cut-point of 33
correctly classified the largest number of subjects (83%).
The specificity of the cut-point at 33 was 98%, but the
sensitivity was only 15% (Fig. 2). If the KDQOL-CF cut-
point were raised to 60, 76% of subjects were correctly
classified, with an acceptable specificity of 82% and a
much higher sensitivity of 52%. The performance char-
acteristics varied slightly by ESRD status. Among ESRD
subjects, a cut-point of 60 had a specificity of 69% and a
sensitivity of 57%. Among CKD subjects, a cut-point of
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Table 2. Correlates of kidney disease Quality of Life Cognitive Function score stratified by chronic kidney disease (CKD) versus end-stage renal
disease (ESRD) status
CKD ESRD
Variable Correlation coefficient P value Variable Correlation coefficient P value
Benzodiazepine use −0.35 0.002 Geriatric Depression Scale −0.54 <0.0001
Albumin 0.30 0.007 Benzodiazepine use −0.40 0.0003
Phosphorus −0.30 0.008 Stroke −0.31 0.005
Calcium × Phosphorus −0.24 0.04 Beta-blocker use 0.23 0.04
Education 0.24 0.03
Table 3. Multivariable predictors of Kidney Disease Quality of Life
Cognitive Function score
Variable b ± SE P value
ESRD 79.95 ± 26.92 0.003
Benzodiazepine use −22.43 ± 4.59 <0.001
Stroke −9.75 ± 3.12 0.002
PVD −8.49 ± 3.31 0.01
Phosphorus per mg/dL −2.87 ± 0.87 0.001
Albumin per mg/dL 10.44 ± 3.59 0.004
Beta-blocker use 8.81 ± 2.75 0.002
Education per year 3.76 ± 1.12 0.001
Albumin × ESRD −14.77 ± 4.93 0.003
Education × ESRD −2.86 ± 1.40 0.04
Intercept 11.32 ± 21.35 0.60
Note: model R2 = 0.42; b , linear regression coefficient, SE, standard error.
60 had a higher specificity of 92%, but a lower sensitivity
of only 33%. Raising the cut-point to 80 in subjects with
CKD improved the sensitivity to 56%, with a somewhat
lower specificity of 83%.
Comparing alternative screening strategies
Employing a screening strategy of 3MS testing only
in patients with a KDQOL-CF score <60 enhanced the
positive predictive value (PPV) and slightly decreased
the negative predictive value (NPV) compared to a strat-
egy of screening with the 3MS in all patients (Table 4).
For example, if the prevalence of dementia were 10%,
prescreening with the KDQOL-CF increased the PPV
from 77% to 91%, and decreased the NPV from 99% to
94%. Such a strategy would miss 44 additional cases of
dementia, and would avoid additional (perhaps unneces-
sary) testing in 786 patients per 1000 patients screened.
Assuming formal cognitive function testing costs $20, a
strategy that included prescreening with the KDQOL-CF
would result in a cost savings of $15,720 per 1000 patients
screened. The benefits of prescreening diminished some-
what as the estimated prevalence of dementia increased.
DISCUSSION
Effectively identifying patients with cognitive impair-
ment requires an accurate screening tool that can be
easily implemented in clinical practice. In this study,
we assessed the validity of the KDQOL-CF subscale, a
simple self-administered questionnaire, with the 3MS, a
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Fig. 2. Receiver operating characteristics (ROC) curve for Kidney Dis-
ease Quality of Life Cognitive Function Scale (3MS <80 as gold stan-
dard).
measure of global cognitive function used widely in
epidemiologic studies [13, 14]. Our results suggest the
KDQOL-CF is a valid instrument for assessing cognitive
function.
We identified several significant predictors of self-
assessed cognitive impairment by the KDQOL-CF, in-
cluding a number of factors and/or conditions associated
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Table 4. Positive and negative predictive values for strategies of dementia screening
Strategy 1 3MS Strategy 2 KDQOL-CF
testing in all followed by 3MS if positive
Dementia False False Additional dementia Additional
prevalence PPV NPV negativesa PPV NPV negativesa cases misseda tests avoideda
2.5% 44% 99% 2 69% 99% 13 11 812
5% 61% 99% 5 82% 97% 26 21 803
7.5% 71% 99% 7 87% 96% 42 35 795
10% 77% 99% 9 91% 94% 53 44 786
15% 84% 98% 14 94% 91% 79 66 769
20% 88% 98% 18 96% 88% 105 87 752
Abbreviations are: 3MS, Modified Mini-Mental State Exam; KDQOL-CF, Kidney Disease Quality of Life Cognitive Function Scale; PPV, positive predictive value;
NPV, negative predictive value. Note: assuming 3MS cut-point <80 has sensitivity of 91% and specificity of 97% and KDQOL-CF cut-point <60 has sensitivity 52%
and specificity 82%.
aPer 1000 patients screened.
with vascular disease, such as stroke, peripheral vascular
disease, hyperphosphatemia, and hypoalbuminemia. The
relation between hypoalbuminemia and self-assessed
cognitive function varied by stage of kidney disease, sug-
gesting malnutrition is a much stronger predictor of cog-
nitive impairment in ESRD versus CKD. Drugs were also
related to KDQOL-CF scores. Specifically, beta-blockers
were associated with higher, and benzodiazepines asso-
ciated with lower, KDQOL-CF scores. There was a non-
significant association between beta-blocker use and 3MS
score (P = 0.07 after adjusting for age, sex, race, and ed-
ucation). In contrast, there was no association between
benzodiazepine use and 3MS score (P = 0.57). There was
no association between the use of opiates or antidepres-
sants and 3MS, KDQOL-CF, or GDS scores.
Interestingly, there were no associations among age,
sex, and race and the KDQOL-CF score (explaining less
than 1% of the variation), in contrast to the 3MS, where
demographics account for 15% of the score’s variation.
The absence of age, sex, and race biases in the KDQOL-
CF may be advantageous. If confirmed in larger studies,
this characteristic of the KDQOL-CF could prove very
useful in socioeconomically and ethnically diverse popu-
lations with CKD and ESRD. The dominant effects of age
and race on the 3MS and other objective tests of cognitive
function have lessened enthusiasm for their widespread
use in screening for dementia [15, 16].
Despite only modest correlation between scores on the
KDQOL-CF and 3MS, the KDQOL-CF accurately clas-
sified 76% of subjects using a cut-point of 60 with rea-
sonable sensitivity and specificity. Exploratory analysis
suggested an alternate cut-point of 33 had high speci-
ficity for diagnosing cognitive impairment. The largest
discrepancies between the two instruments occurred at
the extremes, such that the KDQOL-CF underestimated
impairment at the lowest 3MS scores, and overesti-
mated impairment at the highest 3MS scores. One would
expect these discrepancies with most self-administered
instruments when compared with objective non–self-
administered tests. Persons with poorer cognitive func-
tion may not recognize their own limitations. In contrast,
persons with little or no cognitive impairment may inter-
pret decrements in function (possibly related to physical
disability) as decrements in cognition. Thus, optimal use
of the KDQOL-CF in clinical practice may be as the first
step in a staged evaluation, or in selected patients with
risk factors for cognitive impairment. Such an approach
would maximize efficiency, targeting labor-intensive for-
mal cognitive function testing and associated resources
toward those with a high likelihood of impairment.
Indeed, a strategy of performing 3MS testing only in
those with KDQOL-CF scores <60 would result in con-
siderable improvement in the PPV of dementia screen-
ing with relatively little change in the NPV over a wide
range of prevalence estimates. Although we did not con-
sider the downstream costs of missing a case of dementia
with these screening strategies (or the considerable costs
of a comprehensive dementia evaluation), prescreening
would substantially reduce unneeded formal cognitive
function testing. If the prevalence of dementia in per-
sons with CKD and ESRD were over 25% or more than
twice the age-matched prevalence in the general popula-
tion, prescreening would provide less incremental benefit
over 3MS testing alone.
There are several limitations of this study. We used
scores on the 3MS rather than clinical diagnosis of de-
mentia as the gold standard. The presence of cognitive
impairment is associated with an increased risk of de-
mentia and mortality in the general population [17, 18].
However, longitudinal studies of cognitive impairment
in CKD and ESRD are lacking; thus, whether the pres-
ence of cognitive impairment, and by extension, low 3MS
scores, carry the same prognosis in persons with kidney
disease is unknown. We did not include a control group
in the current study. However, age-, race-, and education-
matched normative data for the 3MS are available from
published sources [19–21]. Each instrument was adminis-
tered only once, although the reliability of both the 3MS
and KDQOL-CF has previously been reported to be high
[4, 9].
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We used the GDS, rather than the more widely used
BDI, to adjust for depressive symptoms because of the
brevity of the GDS. In addition, although not specifically
validated in persons with CKD, its use in persons with
cognitive impairment is well accepted [11]. The strong
correlation between the GDS and KDQOL-CF suggests
overlap between depressive symptoms and cognitive im-
pairment symptoms. Alternatively, the two conditions
may frequently coexist in persons with CKD and ESRD.
Because a more comprehensive depression evaluation
was not performed, this finding deserves further study
before firm conclusions can be reached. Our CKD sub-
jects were predominantly male, reflecting the large am-
bulatory nephrology clinic population at one of the study
sites (San Francisco Veterans Affairs Medical Center).
We had relatively few CKD patients with an estimated
GFR >45 mL/min/1.73 m2. Thus, these results may not
be generalizable to persons with mild CKD. Finally, our
study population, while demographically similar to the
United States ESRD population, may represent a more
highly functional population than average.
The optimal time for administering cognitive tests in
subjects with ESRD is not known. Studies examining
temporal fluctuations in cognitive performance are diffi-
cult to interpret due to differences in study design. Some
studies suggest cognitive performance 24 hours after dial-
ysis is better than nondialyzed ESRD subjects [22], and
not different than medical controls [23]. In a recent study
of hemodialysis and peritoneal dialysis subjects, the au-
thors found significant decrements in the cognitive per-
formance of hemodialysis subjects at 67 hours, but not
24 hours, postdialysis [24]. In contrast, cognitive perfor-
mance in peritoneal dialysis subjects was unchanged, or
in some cases, slightly improved. Others have found no
evidence of temporal changes in cognitive function [25].
Moreover, whether testing should be conducted on or
off dialysis has not been resolved. In the current study,
we chose to test subjects during hemodialysis for several
reasons. First, the largest study of cognitive function in
hemodialysis patients performed cognitive function test-
ing during hemodialysis, thus permitting direct compari-
son to our population’s test results [1]. Second, testing for
all patients were standardized to a midweek hemodialy-
sis day, minimizing potential fluctuations due to uremic
symptoms. Finally, although the optimal timing is debat-
able, administration of the 3MS during dialysis is clinically
most practical. Thus, we hoped to mimic the realities of
clinical practice in the current study.
CONCLUSION
We assessed the validity of the KDQOL-CF subscale
using measured global cognitive function on the 3MS as
the gold standard. Our results provide support for use of
the KDQOL-CF as a screening tool to assess cognitive
impairment in patients with CKD and ESRD, and should
facilitate comparisons of cognitive function among dif-
ferent patient groups in epidemiologic studies utilizing
the KDQOL-CF. Further studies are needed to deter-
mine whether a two-tiered diagnostic approach, or use
of additional instruments, could improve the accuracy of
assessing cognitive function in persons with ESRD and
CKD.
ACKNOWLEDGMENTS
Dr. Kurella was supported by the American Kidney Fund Clinical
Scientist in Nephrology Award. Dr. Chertow was supported by the NIH-
NIDDK RO1 DK58411 and NIH-NIDDK RO1 DK01005. There are
no conflicts of interest associated with this paper.
Reprint requests to Glenn M. Chertow, M.D., MPH, Department of
Medicine Research, University of California San Francisco, UCSF Laurel
Heights Suite 430, 3333 California Street, San Francisco, CA 94118–1211.
E-mail: chertowg@medicine.ucsf.edu
REFERENCES
1. SEHGAL AR, GREY SF, DEOREO PB, WHITEHOUSE PJ: Preva-
lence, recognition, and implications of mental impairment among
hemodialysis patients. Am J Kidney Dis 30:41–49, 1997
2. BROOKMEYER R, GRAY S, KAWAS C: Projections of Alzheimer’s dis-
ease in the United States and the public health impact of delaying
disease onset. Am J Public Health 88:1337–1342, 1998
3. HAYS RD, KALLICH JD, MAPES DL, et al: Development of the kidney
disease quality of life (KDQOL) instrument. Qual Life Res 3:329–
338, 1994
4. RAO S, CARTER WB, MAPES DL, et al: Development of subscales
from the symptoms/problems and effects of kidney disease scales
of the kidney disease quality of life instrument. Clin Ther 22:1099–
1111, 2000
5. FUKUHARA S, LOPES AA, BRAGG-GRESHAM JL, et al: Health-related
quality of life among dialysis patients on three continents: The Dial-
ysis Outcomes and Practice Patterns Study. Kidney Int 64:1903–
1910, 2003
6. FELDMAN HI, APPEL LJ, CHERTOW GM, et al: The Chronic Renal
Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc
Nephrol 14:S148–153, 2003
7. KOREVAAR JC, MERKUS MP, JANSEN MA, et al: Validation of the
KDQOL-SF: A dialysis-targeted health measure. Qual Life Res
11:437–447, 2002
8. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to
estimate glomerular filtration rate from serum creatinine: A new
prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 130:461–470, 1999
9. TENG EL, CHUI HC: The Modified Mini-Mental State (3MS) exam-
ination. J Clin Psychiatry 48:314–318, 1987
10. BURKE WJ, ROCCAFORTE WH, WENGEL SP: The short form of the
Geriatric Depression Scale: A comparison with the 30-item form. J
Geriatr Psychiatry Neurol 4:173–178, 1991
11. GERETY MB, WILLIAMS JW, JR., MULROW CD, et al: Performance
of case-finding tools for depression in the nursing home: Influence
of clinical and functional characteristics and selection of optimal
threshold scores. J Am Geriatr Soc 42:1103–1109, 1994
12. BLAND JM, ALTMAN DG: Statistical methods for assessing agree-
ment between two methods of clinical measurement. Lancet 1:307–
310, 1986
13. EBLY EM, HOGAN DB, PARHAD IM: Cognitive impairment in the
nondemented elderly. Results from the Canadian Study of Health
and Aging. Arch Neurol 52:612–619, 1995
14. GRAHAM JE, ROCKWOOD K, BEATTIE BL, et al: Prevalence and sever-
ity of cognitive impairment with and without dementia in an elderly
population. Lancet 349:1793–1796, 1997
Kurella et al: Validation of the KDQOL Cognitive Function subscale 2367
15. MURDEN RA, MCRAE TD, KANER S, BUCKNAM ME: Mini-Mental
State exam scores vary with education in blacks and whites. J Am
Geriatr Soc 39:149–155, 1991
16. WELSH KA, FILLENBAUM G, WILKINSON W, et al: Neuropsychologic
test performance in African-American and white patients with
Alzheimer’s disease. Neurology 45:2207–2211, 1995
17. DEWEY ME, SAZ P: Dementia, cognitive impairment and mortality
in persons aged 65 and over living in the community: A systematic
review of the literature. Int J Geriatr Psychiatry 16:751–761, 2001
18. BENNETT DA, WILSON RS, SCHNEIDER JA, et al: Natural history of
mild cognitive impairment in older persons. Neurology 59:198–205,
2002
19. BROWN LM, SCHINKA JA, MORTIMER JA, GRAVES AB: 3MS norma-
tive data for elderly African Americans. J Clin Exp Neuropsychol
25:234–241, 2003
20. BRAVO G, HEBERT R: Age- and education-specific reference values
for the Mini-Mental and modified Mini-Mental State Examinations
derived from a non-demented elderly population. Int J Geriatr Psy-
chiatry 12:1008–1018, 1997
21. BORNSTEIN RA: Normative data on selected neuropsychologic
measures from a nonclinical sample. J Clin Psychol 41:651–659,
1985
22. RYAN JJ, SOUHEAVER GT, DEWOLFE AS: Halstead-Reitan Test re-
sults in chronic hemodialysis. J Nerv Ment Dis 169:311–314, 1981
23. PLISKIN NH, YURK HM, HO LT, UMANS JG: Neurocognitive function
in chronic hemodialysis patients. Kidney Int 49:1435–1440, 1996
24. WILLIAMS MA, SKLAR AH, BURRIGHT RG, DONOVICK PJ: Temporal
effects of dialysis on cognitive functioning in patients with ESRD.
Am J Kidney Dis 43:705–711, 2004
25. RATNER DP, ADAMS KM, LEVIN NW, ROURKE BP: Effects of
hemodialysis on the cognitive and sensory-motor functioning of the
adult chronic hemodialysis patient. J Behav Med 6:291–311, 1983
